Total Payments
$726,673
2024 Payments
$112,428
Companies
30
Transactions
543
Medicare Patients
643
Medicare Billing
$177,545
Payment Breakdown by Category
Consulting$497,828 (68.5%)
Research$106,392 (14.6%)
Travel$64,190 (8.8%)
Other$49,477 (6.8%)
Food & Beverage$8,775 (1.2%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $497,828 | 192 | 68.5% |
| Unspecified | $106,392 | 115 | 14.6% |
| Travel and Lodging | $64,190 | 79 | 8.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,047 | 28 | 4.8% |
| Food and Beverage | $8,775 | 122 | 1.2% |
| Honoraria | $7,610 | 4 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,320 | 1 | 0.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.3% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$620,281
428 transactions
Research
$106,392
115 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $133,047 | 90 | $0 (2024) |
| Gilead Sciences, Inc. | $118,904 | 54 | $0 (2024) |
| AstraZeneca UK Limited | $59,746 | 43 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $52,019 | 25 | $0 (2022) |
| F. Hoffmann-La Roche AG | $48,446 | 50 | $0 (2024) |
| Merck Sharp & Dohme LLC | $38,401 | 29 | $0 (2022) |
| PFIZER INC. | $34,707 | 40 | $0 (2024) |
| Radius Health, Inc. | $31,009 | 24 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $29,638 | 25 | $0 (2024) |
| Eli Lilly and Company | $25,054 | 34 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,428 | 59 | Gilead Sciences, Inc. ($46,401) |
| 2023 | $143,227 | 55 | Gilead Sciences, Inc. ($47,701) |
| 2022 | $115,318 | 79 | SANOFI-AVENTIS U.S. LLC ($35,225) |
| 2021 | $72,960 | 72 | F. Hoffmann-La Roche AG ($13,319) |
| 2020 | $90,334 | 69 | Novartis Pharmaceuticals Corporation ($18,995) |
| 2019 | $94,191 | 110 | Novartis Pharmaceuticals Corporation ($24,152) |
| 2018 | $56,843 | 41 | Novartis Pharmaceuticals Corporation ($28,079) |
| 2017 | $41,372 | 58 | Novartis Pharmaceuticals Corporation ($22,637) |
All Payment Transactions
543 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| Category: ONC | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $75.83 | General |
| 12/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $36.56 | General |
| Category: ONC | ||||||
| 12/06/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 12/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 11/25/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,560.00 | General |
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| 09/26/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $71.63 | General |
| Category: ONC | ||||||
| 09/25/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,080.00 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | AstraZeneca UK Limited | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $3,082.50 | General |
| Category: Oncology | ||||||
| 09/13/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 09/13/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $57.77 | General |
| Category: ONC | ||||||
| 09/12/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $76.14 | General |
| 09/04/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| 08/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $6,826.00 | General |
| Category: ONC | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $2,008.00 | General |
| Category: ONC | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $128.04 | General |
| Category: ONC | ||||||
| 08/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $47.51 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Delcath Systems | Hepzato Kit (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $223.20 | General |
| Category: ONC | ||||||
| 08/09/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $47.03 | General |
| Category: ONC | ||||||
| 07/18/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $8,533.00 | General |
| Category: ONC | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/18/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $94.43 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $21,892 | 17 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $14,810 | 10 |
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $10,243 | 2 |
| A study of GDC 9545 given pre surgery in patients with hormone receptor early breast cancer | F. Hoffmann-La Roche AG | $6,824 | 4 |
| GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC | F. Hoffmann-La Roche AG | $5,929 | 6 |
| SHATTUCK: SL-115154 (CSF1R-FC-CD40L) | Takeda Pharmaceuticals U.S.A., Inc. | $5,738 | 4 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $5,522 | 6 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLE PLUS PALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCER | F. Hoffmann-La Roche AG | $5,119 | 5 |
| A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal wom | SANOFI-AVENTIS U.S. LLC | $4,502 | 9 |
| A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer | GENZYME CORPORATION | $4,500 | 12 |
| A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER | F. Hoffmann-La Roche AG | $2,178 | 4 |
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,070 | 1 |
| A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | $1,705 | 2 |
| A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | GENZYME CORPORATION | $1,500 | 2 |
| A Phase 1-2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Wom | GENZYME CORPORATION | $1,467 | 3 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| A Phase 1-2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Canc | GENZYME CORPORATION | $1,247 | 2 |
| NEJM EMERALD manuscript | Radius Health, Inc. | $858.63 | 2 |
| PALBOCIBLIB FULVESTRANT - IPATASERTIB PH3 STUDY IN 1L HR HER2- MBC | F. Hoffmann-La Roche AG | $706.70 | 2 |
| TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK 4 AND OR 6 INHIBITOR | Novartis Pharmaceuticals Corporation | $686.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $631.79 | 2 |
| Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | F. Hoffmann-La Roche AG | $595.22 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $584.00 | 3 |
| SABCS EMERALD presentation | Radius Health, Inc. | $464.82 | 2 |
| Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer | SANOFI-AVENTIS U.S. LLC | $454.29 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $450.00 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DISEASE | Novartis Pharmaceuticals Corporation | $429.00 | 1 |
| Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC) | SANOFI-AVENTIS U.S. LLC | $397.50 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
| SABCS EMERALD abstract | Radius Health, Inc. | $166.68 | 2 |
| EMBER-2: A PHASE 1, OPEN-LABEL, PREOPERATIVE WINDOW STUDY EVALUATING THE BIOLOGICAL EFFECTS OF LY3484356 IN POST-MENOPAUSAL WOMEN WITH STAGE I-III ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER | Eli Lilly and Company | $1.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 121 | 306 | $176,560 | $33,665 |
| 2022 | 3 | 156 | 478 | $259,854 | $52,075 |
| 2021 | 4 | 171 | 462 | $221,230 | $51,577 |
| 2020 | 6 | 195 | 414 | $184,367 | $40,227 |
Total Patients
643
Total Services
1,660
Medicare Billing
$177,545
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 75 | 256 | $156,374 | $29,806 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 35 | $14,135 | $2,647 | 18.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 14 | 15 | $6,051 | $1,212 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 83 | 340 | $203,556 | $40,732 | 20.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 95 | $38,962 | $8,322 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 39 | 43 | $17,336 | $3,021 | 17.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 82 | 297 | $151,233 | $36,555 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 88 | $36,914 | $7,866 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 62 | $20,852 | $4,555 | 21.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $12,231 | $2,600 | 21.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 49 | 168 | $77,778 | $16,396 | 21.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 41 | 133 | $55,575 | $12,302 | 22.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 30 | $24,461 | $5,398 | 22.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 42 | $13,335 | $2,641 | 19.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 24 | 24 | $10,448 | $2,298 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 17 | $2,770 | $1,192 | 43.0% |
About Dr. Aditya Bardia, MD
Dr. Aditya Bardia, MD is a Medical Oncology healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639210107.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aditya Bardia, MD has received a total of $726,673 in payments from pharmaceutical and medical device companies, with $112,428 received in 2024. These payments were reported across 543 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($497,828).
As a Medicare-enrolled provider, Bardia has provided services to 643 Medicare beneficiaries, totaling 1,660 services with total Medicare billing of $177,545. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Santa Monica, CA
- Active Since 02/09/2007
- Last Updated 07/01/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1639210107
Products in Payments
- KISQALI (Drug) $80,597
- Trodelvy (Drug) $75,980
- IBRANCE (Drug) $18,557
- KEYTRUDA (Biological) $14,394
- Non-Covered Product (Drug) $12,854
- ENHERTU (Biological) $11,585
- JEVTANA (Drug) $10,457
- HealthTec (Device) $9,166
- LYNPARZA (Drug) $8,905
- Orserdu (Drug) $8,770
- PIQRAY (Drug) $7,190
- VERZENIO (Drug) $6,982
- Truqap (Drug) $6,165
- AFINITOR (Drug) $6,140
- Lonsurf (Drug) $5,917
- BYL719 (Drug) $5,618
- NERLYNX (Drug) $5,501
- FOUNDATIONACT (Device) $5,137
- SAR439859 (Drug) $4,162
- SAPHNELO (Biological) $3,985
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.